BioCryst Pharmaceuticals (BCRX) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Novavax (NVAX) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 23.7% versus a gain of 13.9%. Over five years, BCRX leads with a -45.2% price change compared with -93.2% for NVAX. BioCryst Pharmaceuticals is the larger company by market cap ($2.12 billion vs $1.82 billion), about 1.2 times the size.
Novavax converts more of its revenue into profit, with a net margin of 39.2% versus 30.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | NVAX |
|---|---|---|
| Share price | $8.29 | $11.01 |
| Market cap | $2.12B | $1.82B |
| 1-day change | -1.31% | -1.87% |
| YTD return | +6.28% | +63.84% |
| 1-year return | +13.87% | +23.71% |
| 5-year return | -45.21% | -93.20% |
| Forward P/E | 8.82 | — |
| EPS (TTM) | $-1.40 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | $1.12B |
| Revenue growth (YoY) | +94.10% | +64.69% |
| Net income (latest FY) | $263.86M | $440.30M |
| Gross margin | 97.82% | 93.50% |
| Operating margin | 38.98% | 40.30% |
| Net margin | 30.16% | 39.19% |
| 52-week high | $11.22 | $13.39 |
| 52-week low | $6.00 | $6.20 |
| Distance from 52-week high | -26.11% | -17.77% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +150.06% | +27.16% |
| Average volume | 4.13M | 5.21M |
| Shares outstanding | 255.54M | 164.95M |
| Employees | 435 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus 30.2 cents for BioCryst Pharmaceuticals.
- BioCryst Pharmaceuticals grew revenue faster in its latest fiscal year (+94.10% vs +64.69%).
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
BCRX vs NVAX FAQ
Which is bigger, BioCryst Pharmaceuticals or Novavax?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $2.12B compared with $1.82B for Novavax (NVAX).
Which stock has performed better over the past year, BCRX or NVAX?
NVAX returned +23.71% over the past 12 months, compared with +13.87% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Novavax in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.